查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542937

全球数位乳房断层合成市场 - 2024-2031

Global Digital Breast Tomosynthesis Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球数位乳房断层合成市场将于 2023 年达到 35 亿美元，预计到 2031 年将达到 62 亿美元，2024-2031 年预测期间复合年增长率为 7.5%

数位乳房断层合成，也称为3D 乳房X 光摄影，是一种检测乳癌（尤其是緻密乳房组织）的高效方法，它使用一系列二维影像来创建三维影像，这与依赖2D 影像的标准乳房X 光摄影不同。

数位乳房断层合成 (DBT) 使用 X 光管从多个角度拍摄乳房的多个 2D 影像。此过程类似于标准乳房X光检查，但乳房被定位并压缩成弧形。然后这些图像被数位化并组合成 3D 图像，从而提供更详细的信息，从而更容易区分健康组织和潜在的癌组织。这种方法提供了更准确、更详细的乳房视图，增强了乳癌筛检的诊断能力。

市场动态：

驱动程式和限制

乳癌盛行率上升

全球乳癌发生率的上升增加了对数位乳房断层合成 (DBT) 等先进诊断工具的需求。 DBT 提供比传统乳房 X 光摄影检查更详细的影像，能够及早发现细微病变。这种增强的检测对于早期介入、改善患者治疗结果和降低死亡率至关重要。因此，对 DBT 系统的需求激增。

例如，世卫组织发布了新的全球乳癌倡议框架，旨在到2040年拯救25亿乳癌患者的生命。乳癌是最常见的成人癌症，95% 的国家将其列为女性癌症死亡的主要原因。然而，生存仍然不公平，80% 的死亡发生在低收入和中等收入国家。

与设备相关的挑战

数位乳房断层合成 (DBT) 市场面临多项挑战，包括高成本、放射科医生的专门培训、潜在的辐射暴露问题、监管障碍和有限的报销政策。这些因素可能会阻碍 DBT 的成长和采用，特别是在较小的医疗机构和发展中地区。

细分市场分析

全球数位乳房断层合成市场根据产品类型、应用、最终用户和地区进行细分。

此产品类型细分市场的2D/3D组合系统约占数位乳房断层合成市场份额的54.1%

产品类型细分中的2D/3D组合系统约占54.1%。 2D/3D 组合系统在数位乳房断层合成 (DBT) 中对于改善乳癌筛检和诊断至关重要。这些系统将传统的 2D 乳房 X 光摄影与先进的 3D 断层合成相结合，提供乳房组织的全面视图。

这种组合可以提高检测率，尤其是在緻密的乳房组织中，并减少误报。它还可以最大限度地减少回电和患者的焦虑。这些系统在临床环境中越来越受到青睐，因为它们能够在单次检查中提供标准的乳房X光摄影视图和增强的诊断能力。

例如，2023 年 11 月，GE HealthCare 推出了 MyBreastAI Suite，这是一款一体化的人工智慧应用平台，旨在帮助临床医生进行乳癌检测并提高工作流程生产力。该套件整合了三个 iCAD 应用程式：用于 DBT 的 ProFound AI、用于 2D 乳房 X 光摄影的 SecondLook 和 PowerLook 密度评估。

市场地域占有率

预计北美在整个预测期内将占据总市场份额的 38.4% 左右

由于乳癌发病率上升、FDA 批准、该地区发达的医疗基础设施、医疗保健支出增加以及其他因素帮助北美市场预计将维持其在整个预测期内的总市场份额，北美预计将占据约38.4% 的市场占有率。

例如，2023 年11 月，美国食品药物管理局(FDA) 批准了Lunit Insight DBT 的510(k) 许可，这是一种支援人工智慧(AI) 的模式，可提供数位乳房断层合成(DBT)影像的辅助评估。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 乳癌盛行率上升
      • 设备的进步
    • 限制
      • 与设备相关的挑战
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 专利分析
  • 大环境分析
  • SWOT分析
  • DMI 意见

第 6 章：依产品类型

  • 2D/3D 组合系统
  • 独立 3D 系统

第 7 章：按申请

  • 放映
  • 诊断

第 8 章：最终用户

  • 医院
  • 诊断中心
  • 其他的

第 9 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Fujifilm
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • GE Healthcare
  • GMM (IMS Giotto)
  • Hologic, Inc
  • Planmeca (Planmed)
  • Siemens Healthineers
  • Philips Healthcare
  • Afga Healthcare
  • Trivitron Healthcare
  • Carestream Health (*LIST NOT EXHAUSTIVE)

第 12 章：附录

简介目录
Product Code: MD990

Report Overview

Global Digital Breast Tomosynthesis Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 6.2 billion by 2031, growing at a CAGR of 7.5% during the forecast period 2024-2031

Digital breast tomosynthesis, also known as 3D mammography, is a highly effective method for detecting breast cancer, particularly in dense breast tissue, using a series of two-dimensional images to create a three-dimensional image, unlike standard mammography which relies on 2D images.

Digital breast tomosynthesis (DBT) uses an X-ray tube to take multiple 2D images of the breast from multiple angles. This process is similar to a standard mammogram but with the breast being positioned and compressed in an arc. The images are then digitized and combined into a 3D image, which provides more detailed information, making it easier to distinguish between healthy and potentially cancerous tissue. This method offers a more accurate and detailed view of the breast, enhancing the diagnostic capabilities of breast cancer screening.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of breast cancer

The rise in breast cancer globally has heightened the need for advanced diagnostic tools like Digital Breast Tomosynthesis (DBT). DBT offers more detailed imaging than traditional mammography, enabling early detection of subtle lesions. This enhanced detection is crucial for early intervention, improving patient outcomes, and reducing mortality rates. As a result, the demand for DBT systems has surged.

For instance, WHO has released a new Global Breast Cancer Initiative Framework, aiming to save 2.5 billion lives from breast cancer by 2040. The framework recommends early detection, timely diagnosis, and comprehensive management of the disease. Breast cancer is the most common adult cancer, with 95% of countries having it as the leading cause of female cancer deaths. However, survival remains inequitable, with 80% of deaths occurring in low- and middle-income countries.

Challenges associated with the devices

The Digital Breast Tomosynthesis (DBT) market faces several challenges, including high costs, specialized training for radiologists, potential radiation exposure concerns, regulatory hurdles, and limited reimbursement policies. These factors can hinder the growth and adoption of DBT, especially in smaller healthcare facilities and developing regions.

Market Segment Analysis

The global digital breast tomosynthesis market is segmented based on product type, application, end-user, and region.

The 2D/3D combination systems from the product type segment accounted for approximately 54.1% of the digital breast tomosynthesis market share

The 2D/3D combination systems from the product type segment accounted for approximately 54.1%. 2D/3D combination systems are essential in Digital Breast Tomosynthesis (DBT) for improving breast cancer screening and diagnosis. These systems combine traditional 2D mammography with advanced 3D tomosynthesis, providing a comprehensive view of breast tissue.

This combination leads to better detection rates, especially in dense breast tissue, and reduces false positives. It also minimizes callbacks and patient anxiety. These systems are increasingly preferred in clinical settings due to their ability to provide standard mammographic views and enhanced diagnostic capabilities in a single examination.

For instance, in November 2023, GE HealthCare launched MyBreastAI Suite, an all-in-one platform of AI apps, designed to aid clinicians in breast cancer detection and enhance workflow productivity. The suite integrates three iCAD applications, ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to rising breast cancer incidence, FDA clearance, the region's developed healthcare infrastructure, increasing healthcare spending and other factors help the North American market is expected to maintain its dominance over the forecast period.

For instance, in November 2023, the Food and Drug Administration (FDA) granted 510(k) clearance for Lunit Insight DBT, an artificial intelligence (AI)-enabled modality that provides an adjunctive assessment of digital breast tomosynthesis (DBT) images.

Market Segmentation

By Product Type

  • 2D/3D Combination systems
  • Standalone 3D Systems

By Application

  • Screenings
  • Diagnostic

By End User

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the market include Fujifilm, GE Healthcare, GMM (IMS Giotto), Hologic, Inc., Planmeca (Planmed), Siemens Healthineers, Philips Healthcare, AGFA Healthcare, Trivitron Healthcare, Carestream Health among others.

Key Developments

  • In July 2024, LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic monitors with the new 21HQ613D-B, which was recently cleared by the U.S. Food and Drug Administration for sale in the U.S.

Why Purchase the Report?

  • To visualize the global digital breast tomosynthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the digital breast tomosynthesis market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global digital breast tomosynthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of breast cancer
      • 4.1.1.2. Advancements in the devices
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with the devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. 2D/3D Combination systems *
    • 6.2.1. Introduction
  • 6.3. Standalone 3D Systems

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.2. Market Attractiveness Index, By Application
  • 7.3. Screenings*
    • 7.3.1. Introduction
    • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.4. Diagnostic

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Centers
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Fujifilm *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. GE Healthcare
  • 11.3. GMM (IMS Giotto)
  • 11.4. Hologic, Inc
  • 11.5. Planmeca (Planmed)
  • 11.6. Siemens Healthineers
  • 11.7. Philips Healthcare
  • 11.8. Afga Healthcare
  • 11.9. Trivitron Healthcare
  • 11.10. Carestream Health (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us